Subscribe to RSS
From the Editor’s Desk
06 May 2018 (online)
I am happy to present this knowledge providing new insights about epilepsy diagnosis treatment which remains critical for improving the quality of lives for people with epilepsy.
In this current issue of IJEP many articles on research, etiology, diagnostics and therapeutics, interesting diagnostically difficult cases, practical problems in Epilepsy have been accepted for publication. The topics covered in this issue are drug metabolite and PIGO (Phenytoin Influenced Gingival Overgrowth), Receptors modulators of caffeine-induced seizures, Cognitive deficits after first seizure, DNA damage and mutation screening in epilepsy patients, Medial Temporal Lobe Atrophy with Seizures in AD (Alzheimer’s disease), Sargassum Oligocystum effects in PTZ (Pentylenetetrazole-induced seizures) seizures, Gabapentin and Levetricetam Interacts with Lipids, Taurine supplementation to anti-seizure drugs, Mimic Of Tay − Sachs Disease GM2 activator protein deficiency, A Fatal Case of Valproate-Induced Hyperammonemic Encephalopathy, Disseminated Cysticercosis, Hypermotor Seizures without Involvement of the Frontal Lobes Hypermotor Seizure, Involvement of N-methyl-d-aspartate receptors and nitric oxide in the anticonvulsant effects of dantrolene against Pentylenetetrazole-induced seizures in mice. The journal also includes 10 Multiple Choice Questions (MCQs) made de novo by our experts.
I would like to sincerely thank our hard working authors and the collective effort of our co-editors, associate editors, section editors and editorial board members who amiably devoted their time and efforts. The articles in this journal signify enduring medical research in Epilepsy diagnosis and treatment.
We hope that you all will enjoy reading it and will find useful methodology, data, concepts and ideas that can facilitate your research needs and implementation of that data and information in your routine clinical practice.
Your valuable suggestions/inputs are solicited.
Best wishes for the year 2018 and years to come.